|
|
.
NPI Detail
NPI: 1326015777
Type: Organization
Taxonomy Code: 282N00000X
Hospital-General
Hospitals/General Acute Care Hospital
1400 XXXXXXX XX
DENVER, CO 802062762
Mailing and Business location phone:
(XXX) XXX-XXXX
|
Click here for new NPI search.
|
2021 OPPS Part A Medicare Services Submitted NPI-1326015777*
OPPS Payment Method "A" - Services not paid under OPPS; uses a different fee schedule (e.g., ambulance, PT, mammography)
Top Level I HCPC Procedures
| Procedure | Description | Number Submitted | Medicare Payment |
| 97110
|
THERAPEUTIC EXERCISES
|
XXXXX
|
$XXXXX.XX
|
| 87186
|
MICROBE SUSCEPTIBLE MIC
|
XXXXX
|
$XXXXX.XX
|
| 36415
|
ROUTINE VENIPUNCTURE
|
XXXX
|
$XXXX
|
| 95004
|
PERCUT ALLERGY SKIN TESTS
|
XXXX
|
$XXXXX.XX
|
| 85025
|
COMPLETE CBC W/AUTO DIFF WBC
|
XXXX
|
$XXXX.XX
|
| 87798
|
DETECT AGENT NOS DNA AMP
|
XXXX
|
$XXXXX.XX
|
| 87181
|
MICROBE SUSCEPTIBLE DIFFUSE
|
XXXX
|
$XXXXX.XX
|
| 80053
|
COMPREHEN METABOLIC PANEL
|
XXXX
|
$XXXX.XX
|
| 94729
|
CO/MEMBANE DIFFUSE CAPACITY
|
XXXX
|
-
|
| 95044
|
ALLERGY PATCH TESTS
|
XXXX
|
$XXXX.XX
|
| 71250
|
CT THORAX DX C-
|
XXXX
|
$XXXXXX.XX
|
Top Drugs Administered Other than Oral Method
| Procedure | Description | Number Submitted | Medicare Payment |
| J0256
|
Alpha 1 proteinase inhibitor
|
XXXXXX
|
$XXXXXX.XX
|
| J9271
|
Inj pembrolizumab
|
XXXXX
|
$XXXXXXX.XX
|
| J2182
|
Injection, mepolizumab, 1mg
|
XXXXX
|
$XXXXXX.XX
|
| J1442
|
Inj filgrastim excl biosimil
|
XXXXX
|
$XXXXX.XX
|
| J9299
|
Injection, nivolumab
|
XXXXX
|
$XXXXXX.XX
|
| J1439
|
Inj ferric carboxymaltos 1mg
|
XXXXX
|
$XXXXX.XX
|
| J2357
|
Omalizumab injection
|
XXXXX
|
$XXXXXX.XX
|
| J1459
|
Inj ivig privigen 500 mg
|
XXXXX
|
$XXXXXX.XX
|
| J1756
|
Iron sucrose injection
|
XXXXX
|
-
|
| J9025
|
Azacitidine injection
|
XXXXX
|
$XXXX.XX
|
| J9312
|
Inj., rituximab, 10 mg
|
XXXXX
|
$XXXXXX.XX
|
| J9263
|
Oxaliplatin
|
XXXXX
|
-
|
| J0897
|
Denosumab injection
|
XXXXX
|
$XXXXXX.XX
|
| J1561
|
Gamunex-c/gammaked
|
XXXXX
|
$XXXXXX.XX
|
| J9144
|
Daratumumab, hyaluronidase
|
XXXX
|
$XXXXXX.XX
|
| J1453
|
Fosaprepitant injection
|
XXXX
|
$XXXX.XX
|
| J0517
|
Inj., benralizumab, 1 mg
|
XXXX
|
$XXXXXX.XX
|
| J9305
|
Inj. pemetrexed nos 10mg
|
XXXX
|
$XXXXXX.XX
|
| J9119
|
Inj., cemiplimab-rwlc, 1 mg
|
XXXX
|
$XXXXXX.XX
|
| J9267
|
Paclitaxel injection
|
XXXX
|
-
|
| J2796
|
Romiplostim injection
|
XXXX
|
$XXXXXX.XX
|
| J9171
|
Docetaxel injection
|
XXXX
|
-
|
| J9173
|
Inj., durvalumab, 10 mg
|
XXXX
|
$XXXXXX.XX
|
| J1745
|
Infliximab not biosimil 10mg
|
XXXX
|
$XXXXX.XX
|
| J9264
|
Paclitaxel protein bound
|
XXXX
|
$XXXXX.XX
|
| J0129
|
Abatacept injection
|
XXXX
|
$XXXXXX.XX
|
Top HCPC Level II Procedures / Professional Services
| Procedure | Description | Number Submitted | Medicare Payment |
| G0463
|
Hospital outpt clinic visit
|
XXXXX
|
$XXXXXXX.XX
|
* Medicare Part A utilization data is derived from the 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
|
